Compare DNUT & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNUT | BIOA |
|---|---|---|
| Founded | 1937 | 2015 |
| Country | United States | United States |
| Employees | N/A | 62 |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 606.8M | 681.9M |
| IPO Year | 2021 | N/A |
| Metric | DNUT | BIOA |
|---|---|---|
| Price | $3.50 | $15.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $4.15 | ★ $51.50 |
| AVG Volume (30 Days) | ★ 2.3M | 369.2K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,522,616,000.00 | N/A |
| Revenue This Year | $0.55 | $720.93 |
| Revenue Next Year | $3.59 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.58 | $4.07 |
| 52 Week High | $5.73 | $24.00 |
| Indicator | DNUT | BIOA |
|---|---|---|
| Relative Strength Index (RSI) | 52.37 | 43.68 |
| Support Level | $3.46 | $15.49 |
| Resistance Level | $3.60 | $19.01 |
| Average True Range (ATR) | 0.15 | 1.16 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 66.38 | 37.45 |
Krispy Kreme Inc is a sweet-treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations world-wide. It derives maximum revenue from the U.S. segment.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.